Patrick McCauley Joins MannKind as Chief Commercial Officer
July 12 2017 - 9:00AM
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD)
today announced that Patrick McCauley, J.D., M.B.A., has joined the
company as its Chief Commercial Officer with full responsibilities
for leading MannKind’s commercial operations on a global basis,
effective immediately. Mr. McCauley will report directly to Michael
Castagna, Pharm.D., Chief Executive Officer and will serve on the
company’s executive leadership team. Mr. McCauley takes the Chief
Commercial Officer role previously held by Dr. Castagna.
Mr. McCauley joins MannKind with over 25 years
of experience in the biopharmaceutical industry. He has spent the
last twelve years at Astellas Pharma in a series of senior sales
and compliance leadership roles of increasing responsibility. Prior
to Astellas, Mr. McCauley was a member of the U.S.
commercialization team and held a sales leadership role with
Yamanouchi Pharma before the merger of Yamanouchi and Fujisawa
Pharma to create Astellas in 2005. Before Astellas/Yamanouchi, Mr.
McCauley spent thirteen years with DuPont Pharmaceuticals and one
year with Bristol-Myers Squibb, which acquired DuPont
Pharmaceuticals in 2001. At DuPont and Bristol-Myers Squibb, Mr.
McCauley held a series of leadership roles across the sales,
contracting and pricing, and clinical areas. Throughout his various
career moves, Mr. McCauley has developed deep commercial expertise
serving both specialty and primary care healthcare providers. He
received a MBA degree from the Kellogg School of Management at
Northwestern University, a JD from the South Texas College of Law,
and a BA in Economics from the University of Notre Dame.
“Pat is an exceptional addition to our executive
leadership team and he will be a huge asset for us as we transform
MannKind into a world class company,” said Dr. Castagna, Chief
Executive Officer of MannKind. “I expect Pat will help us to
accelerate the growth of Afrezza and pipeline products to come, and
position our company to deliver strong results in the years
ahead.”
Mr. McCauley commented, “MannKind’s future is
undoubtedly bright and I am thrilled to be a part of the company.
Afrezza is an innovative product with the attributes that I believe
can provide benefits to patients battling diabetes in this
unfortunately large area of unmet medical need.”
About MannKind
CorporationMannKind Corporation (NASDAQ:MNKD) (TASE:MNKD)
focuses on the discovery and development of therapeutic products
for patients with diseases such as diabetes. MannKind
maintains a website at http://www.mannkindcorp.com to which
MannKind regularly posts copies of its press releases as well as
additional information about MannKind. Interested persons can
subscribe on the MannKind website to e-mail alerts that are sent
automatically when MannKind issues press releases, files its
reports with the Securities and Exchange Commission or posts
certain other information to the website.
Forward-Looking Statements This
press release contains forward-looking statements that involve
risks and uncertainties, including statements regarding the
commercial potential of Afrezza. Words such as “believes”,
“anticipates”, “plans”, “expects”, “intend”, “will”, “goal",
“potential” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
are based upon the MannKind’s current expectations. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, the
risks detailed in MannKind’s filings with the Securities and
Exchange Commission, including the Annual Report on Form 10-K for
the year ended December 31, 2016 and subsequent periodic reports on
Form 10-Q and current reports on Form 8-K. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and MannKind undertakes no obligation to
revise or update any forward-looking statements to reflect events
or circumstances after the date of this press release.
Company Contact:
Rose Alinaya
Acting Chief Financial Officer
661-775-5300
ralinaya@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024